Olmesartan medoxomil decreases serum cystatin C levels in hypertensive patients, suggesting that this agent can counteract renal damage, according to a study published in Blood Pressure (2009; published online ahead of print). The drug also reduces left ventricular hypertrophy.
The study, by researchers at Duzce University in Duzce, Turkey, included 44 patients with newly diagnosed hypertension.
They were treated with olmesartan medoxomil 20 mg/day and had six months of follow-up.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.